View downloadable slides from top experts in the field to learn about the latest developments in HER2+ breast cancer. The changing natural history of HER2+ disease, adjuvant strategies to improve patient outcomes, and management of metastatic disease are covered.
Oct 22, 2018
Oct 22, 2019
- Michael Untch, MD, PhD, HELIOS Klinikum Berlin-Buch, Berlin, Germany
The changing natural history of HER2+ breast cancer
- Miguel Martín, MD, PhD, Complutense University, Hospital General Universitario Gregorio Marañon, Madrid, Spain
Preventing recurrent disease: How can we bring new adjuvant therapeutic opportunities to the clinic?
- John Crown, MD, FRCPI, St. Vincent's University Hospital, Dublin, Ireland
HER2+ metastatic breast cancer in 2018: Is this as good as it gets?
- Hope S. Rugo, MD, FASCO, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
This educational activity is specifically designed to educate medical oncologists, breast oncologists, and other healthcare providers who treat patients with breast cancer.
After successful completion of this educational activity, participants should be able to:
- Describe the evolution of HER2+ breast cancer in the current era of HER2-targeted treatments and the remaining areas of unmet medical need
- Evaluate the results of recent clinical trials in HER2+ early breast cancer that explore the evolution of adjuvant treatment strategies and the need for a risk-adapted strategy
- Assess recent developments in HER2-targeted treatment and the opportunities provided by novel agents for HER2+ metastatic breast cancer
- Identify supportive care interventions to minimize adverse events with HER2-targeted therapy
This educational activity is supported by a grant from Puma Biotechnology.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Crown has disclosed that he received honoraria for promotional speakers’ bureaus from Boehringer Ingelheim, Eisai, Genomic Health, Merck Serono, Pfizer, and Puma Biotechnology. He is also independently contracted by Boehringer Ingelheim, GSK, Puma Biotechnology, and Roche. He has ownership interest with Oncomark LTD. He also disclosed receipt of travel support from AbbVie, MSD, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Martín has disclosed that he received consulting fees from AstraZeneca, Genentech, Lilly, Novartis, Pfizer, and Roche. He is also independently contracted by Novartis and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Rugo has disclosed research support for clinical trials through the University of California from Daiichi, Eisai, Genentech, Lilly, Macrogenics, Merck, Novartis, OBI, Odonate, Pfizer, and Plexxikon. She also disclosed receipt of travel support from Amgen, Lilly, Merck, Mylan, Pfizer, and Puma Biotechnology. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Untch has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – consulting fees for advising on clinical trial protocol development from Amgen, Astellas, and Boehringer Ingelheim; intellectual property rights as co-inventor and patent holder of biomarker under development by Inbiomotion; independent medical education lectures at symposia supported by Amgen, Eisai, and Genomic Health; and travel expenses from Amgen for presentation of clinical trial data at ASCO 2018 conference
- Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
- Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.